Anixa Biosciences, Inc.
As of Oct 22, 2026, Anixa Biosciences is in Stage 3, the topping phase, now in week 4 (since Sep 25, 2026). It closed at $2.78, 46.7% below its 52-week high and below its 200-day average, which is falling.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ANIX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ANIX among Biotechnology293rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …293 | ANIX | Stage 3 · wk 4 | 31 | +1.1% |
Anixa Biosciences: quick answers
What stage is Anixa Biosciences in?
As of Oct 22, 2026, Anixa Biosciences (ANIX) is in Stage 3, the topping phase. It entered Stage 3 on Sep 25, 2026 and is in week 4. What the four stages mean
Is Anixa Biosciences in an uptrend?
Its uptrend has stalled. Anixa Biosciences is in Stage 3, the topping phase that follows an advance. It trades 6.4% below its 200-day average, which is falling.
How far is Anixa Biosciences from its 52-week high?
Anixa Biosciences closed at $2.78 on Oct 22, 2026, 46.7% below its 52-week high of $5.22. Its 52-week low is $2.35.
How has Anixa Biosciences performed over the past year?
As of Oct 22, 2026, Anixa Biosciences is down 33.5% over the past year and down 12.0% so far in 2026.
Which sector and industry is Anixa Biosciences in?
Anixa Biosciences is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.